Search

Your search keyword '"Dive, Dominique"' showing total 124 results
Start Over Author "Dive, Dominique"
124 results on '"Dive, Dominique"'

4. Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Author

Lambert, Nicolas, Dauby, Solene, Dive, Dominique, Sadzot, Bernard, and Maquet, Pierre

Subjects
Leukoencephalopathy, Progressive multifocal -- Drug therapy -- Case studies, Health
Abstract

Progressive multifocal leukoencephalopathy (PML) is a devastating infectious disease of the brain that is caused by JC virus (JCV) in the context of cellular immunodeficiency. To date, no effective antiviral [...]

Published
2022

7. Indications de l’autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques

Author

Zephir, Helène, Puyade, Mathieu, Gueguen, Antoine, Michel, Laure, Terriou, Louis, Dive, Dominique, Laureys, Guy, Mathey, Guillaume, Labauge, Pierre, Marjanovic, Zora, Pugnet, Grégory, Badoglio, Manuela, Lansiaux, Pauline, Yakoub-Agha, Ibrahim, Béguin, Yves, and Farge, Dominique

Published
2019
Full Text
View/download PDF

9. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

Author

Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D’Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, and Van de Velde, Ann

Published
2018
Full Text
View/download PDF

12. Brain age as a surrogate marker for cognitive performance in multiple sclerosis

Author

Denissen, Stijn, primary, Engemann, Denis Alexander, additional, De Cock, Alexander, additional, Costers, Lars, additional, Baijot, Johan, additional, Laton, Jorne, additional, Penner, Iris‐Katharina, additional, Grothe, Matthias, additional, Kirsch, Michael, additional, D'hooghe, Marie Beatrice, additional, D'Haeseleer, Miguel, additional, Dive, Dominique, additional, De Mey, Johan, additional, Van Schependom, Jeroen, additional, Sima, Diana Maria, additional, and Nagels, Guy, additional

Published
2022
Full Text
View/download PDF

14. Brain age as a surrogate marker for information processing speed in multiple sclerosis

Author

Denissen, Stijn, primary, Engemann, Denis Alexander, additional, De Cock, Alexander, additional, Costers, Lars, additional, Baijot, Johan, additional, Laton, Jorne, additional, Penner, Iris-Katharina, additional, Grothe, Matthias, additional, Kirsch, Michael, additional, D'hooghe, Marie Beatrice, additional, D'Haeseleer, Miguel, additional, Dive, Dominique, additional, De Mey, Johan, additional, Van Schependom, Jeroen, additional, Sima, Diana Maria, additional, and Nagels, Guy, additional

Published
2021
Full Text
View/download PDF

17. Predicted brain age as a cognitive biomarker in multiple sclerosis

Author

Denissen, Stijn, De Cock, Alexander, Costers, Lars, Baijot, Johan, Laton, Jorne, D'hooghe, Marie Beatrice, D'haeseleer, Miguel, Dive, Dominique, Johan, De Mey, Van Schependom, Jeroen, Sima, Diana Maria, Nagels, Guy, Artificial Intelligence supported Modelling in clinical Sciences, Faculty of Medicine and Pharmacy, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Supporting clinical sciences, Body Composition and Morphology, Medical Imaging, Translational Imaging Research Alliance, Radiology, and Electronics and Informatics

Subjects
Brain Age, multiple sclerosis, artificial intelligence, MRI
Published
2020

18. Decoding the edss scores of multiple sclerosis patients from mri biomarkers

Author

Paolella, Roberto, De La Rosa, Ezequiel, Anania, Vincenzo, Denissen, Stijn, Van Schependom, Jeroen, Nagels, Guy, Dive, Dominique, Durand-Dubief, Françoise, Sappey-Marinier, Dominique, Smeets, Dirk, Sima, Diana Maria, Artificial Intelligence supported Modelling in clinical Sciences, Faculty of Medicine and Pharmacy, Clinical sciences, Electronics and Informatics, Neuroprotection & Neuromodulation, and Neurology

Subjects
Machine Learning, multiple sclerosis, artificial intelligence, MRI
Published
2020

22. Deciphering the Morphology of Motor Evoked Potentials

Author

Yperman, Jan, primary, Becker, Thijs, additional, Valkenborg, Dirk, additional, Hellings, Niels, additional, Cambron, Melissa, additional, Dive, Dominique, additional, Laureys, Guy, additional, Popescu, Veronica, additional, Van Wijmeersch, Bart, additional, and Peeters, Liesbet M., additional

Published
2020
Full Text
View/download PDF

23. Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

Author

Hunter, Samuel F., Aburashed, Rany A., Alroughani, Raed, Chan, Andrew, Dive, Dominique, Eichau, Sara, Kantor, Daniel, Kim, Ho Jin, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, Scott, Thomas, Sharrack, Basil, Wiendl, Heinz, Chung, Luke, Daizadeh, Nadia, Baker, Darren P., and Vermersch, Patrick

Published
2021
Full Text
View/download PDF

24. Short-term MRI-based Prediction of Clinical MS Progression in a Real World Setting

Author

Van Hecke, Wim, Sima, Diana, Billiet, Thibo, Van Schependom, Jeroen, Ernon, Christine, D'Hooghe, Marie, Dive, Dominique, Nagels, Guy, Smeets, Dirk, Electronics and Informatics, Clinical sciences, Neuroprotection & Neuromodulation, and Neurology

Subjects
Neuroscience(all), Clinical MS Progression, Short-term MRI-based Prediction
Published
2019

26. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Author

Rouzaud, Claire, Hautecoeur, Patrick, Donze, Cécile, Heinzlef, Olivier, Dinh, Aurélien, Creange, Alain, Abdullatif, Alkhedr, Audouin, Bertrand, Tourbah, Ayman, Berger, Eric, Bourre, Bertrand, Brochet, Bruno, Mekies, Claude, Cabre, Philippe, Papeix, Caroline, Casez, Olivier, Brassat, David, Defer, Gilles, Derache, Nathalie, De Seze, Jérôme, Dive, Dominique, LePage, Emmanuelle, Fromont, Agnes, Gouider, Riadh, Edan, Gilles, Pelletier, Jean, Grimaud, Jérôme, Guennoc, Anne-Marie, Camdessanché, Jean-Philippe, Kwiatkowski, Arnaud, Laplaud, David, Lebrun, Christine, Debouverie, Marc, Coustans, Marc, Gout, Olivier, La Rochelle, Olivier Anne, Ouallet, Jean-Christophe, Cavelou, Pierre, Labauge, Pierre, Vermersch, Patrick, Wiertlewski, Sandrine, Vukusic, Sandra, Marignier, Romain, Schluep, Myriam, Seeldrayers, Pierrette, Slassi, Ilham, Stankoff, Bruno, Thaite, Frederic, Moreau, Thibault, Thouvenot, Eric, Zephir, Hélène, Ciron, Jonhatan, Collongues, Nicolas, Kerschen, Philippe, Cohen, Mikael, Gueguen, Antoine, Mathey, Guillaume, Carra, Clarisse, Bernady, Patricia, Faucheux, Jean Marc, Planque, Evelyne, Donze, Cecile, Ruet, Aurélie, Mouzawakh, Catherine, and Pittion, Sophie

Published
2017
Full Text
View/download PDF

27. Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus (Acta Neurologica Belgica, (2018), 118, 1, (7-11), 10.1007/s13760-018-0882-3)

Author

Lambert, Catherine, Dubois, Bénédicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, and Janssens, Ann

Subjects
Multiple sclerosis, Platelet count, Practical recommendations, Généralités, Alemtuzumab, Immune thrombocytopenia
Abstract

The article Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus, written by Lambert et al. was originally published electronically on the publisher’s internet portal on 27 January 2018 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on March 3, 2018 to © The Author(s) 2018 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The original article has been corrected., SCOPUS: er.j, info:eu-repo/semantics/published

Published
2018

32. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de neurologie, Lambert, Catherine, Dubois, Benedicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, Janssens, Ann, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de neurologie, Lambert, Catherine, Dubois, Benedicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, and Janssens, Ann

Abstract

Alemtuzumab (Lemtrada) is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features. Alemtuzumab demonstrated superior efficacy over active comparator in both treatment naive patients and those with inadequate response to prior therapy. Alemtuzumab is associated with a consistent and manageable safety and tolerability profile. Treatment with alemtuzumab for multiple sclerosis increases the risk for autoimmune adverse events including immune thrombocytopenia (ITP). Complete blood counts with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter for 48 months after the last infusion. After this period of time, testing should be performed based on clinical findings suggestive of ITP. If ITP onset is confirmed, appropriate medical intervention should be promptly initiated, including immediate referral to a specialist. This paper presents the consensus of Belgian multiple sclerosis specialists and hematologists to guide the treating physician with practical recommendations.

Published
2018

33. Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de neurologie, Lambert, Catherine, Dubois, Benedicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, Janssens, Ann, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de neurologie, Lambert, Catherine, Dubois, Benedicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, and Janssens, Ann

Abstract

The article Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus, written by Lambert et al., was originally published electronically on the publisher's internet portal on 27 January 2018 without open access.

Published
2018

34. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Author

UCL - (SLuc) Service de neurologie, UCL - (SLuc) Service d'hématologie, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D'Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, Van de Velde, Ann, UCL - (SLuc) Service de neurologie, UCL - (SLuc) Service d'hématologie, UCL - SSS/IONS - Institute of NeuroScience, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Laureys, Guy, Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D'Haeseleer, Miguel, De Becker, Ann, Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, and Van de Velde, Ann

Abstract

Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous hematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality, and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardized protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous hematopoietic stem cell transplantation in multiple sclerosis.

Published
2018

35. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

Author

Laureys, G., Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D’haeseleer, Miguel, De Becker, A., Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, Van de Velde, Ann, Laureys, G., Willekens, Barbara, Vanopdenbosch, Ludo, Deryck, Olivier, Selleslag, Dominik, D’haeseleer, Miguel, De Becker, A., Dubois, Bénédicte, Dierickx, Daan, Perrotta, Gaetano, De Wilde, Virginie, Van Pesch, Vincent, Straetmans, Nicole, Dive, Dominique, Beguin, Yves, Van Wijmeersch, Bart, Theunissen, Koen, Kerre, Tessa, and Van de Velde, Ann

Abstract

Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous hematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality, and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardized protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous hematopoietic stem cell transplantation in multiple sclerosis., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

36. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus

Author

Sprangers, Ben, Decoo, Dany, Dive, Dominique, Lysandropoulos, Andreas, Vanopdenbosch, Ludo, Bovy, Christophe, Sprangers, Ben, Decoo, Dany, Dive, Dominique, Lysandropoulos, Andreas, Vanopdenbosch, Ludo, and Bovy, Christophe

Abstract

Alemtuzumab is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting multiple sclerosis with active disease. Multiple sclerosis (MS) patients treated with alemtuzumab are at increased risk for autoimmune adverse events (thyroid disorders, immune thrombocytopenia, and renal disease). The use of alemtuzumab has been associated with the development of renal immune-mediated adverse events in 0.3% of patients in clinical trials in MS, which generally occurred within 39 months of the last administration. Both anti-GBM disease and membranous nephropathy have been associated with the use of alemtuzumab. Early detection is necessary to allow for early diagnosis and prevent adverse renal and patient outcomes. Through the implementation of the risk minimization measures, patients can be diagnosed, and treated if needed, early allowing for generally favorable outcomes. This important goal can be reached through health care professional and patient education, careful analysis of the monthly lab tests, and close collaboration between the patient, neurologist, and the nephrologist. This article presents the consensus of Belgian MS specialists and nephrologists on the practicalities of diagnosis, management, and treatment of alemtuzumab-associated renal adverse events based on good clinical practice., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

38. Disability Improvement Is Observed in Each Functional System in Alemtuzumab-Treated Patients With Active RRMS: Results From CARE-MS II Extension (P6.364)

Author

Hunter, Samuel F., primary, Aburashed, Rany A., additional, Alroughani, Raed, additional, Bromley, Steven M., additional, Dive, Dominique, additional, Izquierdo, Guillermo, additional, Kim, Ho Jin, additional, Lycke, Jan, additional, Macdonell, Richard AL., additional, Pozzilli, Carlo, additional, Sharrack, Basil, additional, Vermersch, Patrick, additional, Lysandropoulos, Andreas, additional, Chung, Luke, additional, Daizadeh, Nadia, additional, and Wiendl, Heinz, additional

Published
2018
Full Text
View/download PDF

39. Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) (P6.368)

Author

Van Wijmeersch, Bart, primary, Boyko, Alexey N., additional, Broadley, Simon, additional, Brassat, David, additional, Dive, Dominique, additional, Hupperts, Raymond MM., additional, Lycke, Jan, additional, Montalban, Xavier, additional, Sharrack, Basil, additional, Wray, Sibyl, additional, Margolin, David H., additional, Chung, Luke, additional, Daizadeh, Nadia, additional, Chirieac, Madalina, additional, and Wiendl, Heinz, additional

Published
2018
Full Text
View/download PDF

40. Corticosteroids in the management of acute multiple sclerosis exacerbations.

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Smets, Ide, Van Deun, Laura, Bohyn, Cedric, Van Pesch, Vincent, Vanopdenbosch, Ludo, Dive, Dominique, Bissay, Véronique, Dubois, Bénédicte, Belgian Study Group for Multiple Sclerosis, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Smets, Ide, Van Deun, Laura, Bohyn, Cedric, Van Pesch, Vincent, Vanopdenbosch, Ludo, Dive, Dominique, Bissay, Véronique, Dubois, Bénédicte, and Belgian Study Group for Multiple Sclerosis

Abstract

Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the central nervous system characterized in the majority of the patients by a relapsing-remitting disease course. For decades high-dosage corticosteroids (CS) are considered the cornerstone in the management of acute MS relapses. However, many unanswered questions remain when it comes to the exact modalities of CS administration. In this review on behalf of the Belgian Study Group for MS we define the efficacy of CS in reducing MS-related morbidity and examine whether the effect is different according to type of CS, route of administration, cumulative dosage, timing of initiation and disease course. We also review the use of CS in combination with other MS treatments and during pregnancy and lactation. Furthermore, we delineate the relevant adverse events due to a pulse CS regimen and present a decision tree that can be used when treating MS relapses in clinical practice.

Published
2017

41. THUR 193 Alemtuzumab improves disability across functional systems

Author

Sharrack Basil, Izquierdo Giullermo, Kim Ho Jin, Macdonell Richard, Aburashed Rany, Hunter Samuel, Alroughani Raed, Lycke Jan, and Dive Dominique

Subjects
medicine.medical_specialty, Expanded Disability Status Scale, business.industry, Functional system, Psychiatry and Mental health, Internal medicine, medicine, Alemtuzumab, Surgery, Treatment effect, In patient, Neurology (clinical), business, medicine.drug
Abstract

The effect of alemtuzumab on functional systems (FS) scores of the Expanded Disability Status Scale (EDSS) was assessed in CARE-MS II patients over 6 years (y) (CARE-MS II, NCT00548405; extension, NCT00930553). Patients received alemtuzumab (12 mg/day; 2 courses: baseline, 5 days; 12 months later, 3 days), and as-needed alemtuzumab retreatment for relapse/MRI activity in the extension or another disease-modifying therapy per investigator discretion. Assessments: Proportion of patients achieving stable/improved EDSS score (versus core study baseline), FS scores, and 6 month confirmed disability improvement (CDI). In patients who achieved CDI over 6 y (n=126), assessments at 6 months post-CDI onset: EDSS score (1 FS. Improvements were observed in each FS, most frequently Sensory (48%), Pyramidal (44%), and Cerebellar (44%) systems; 21%–25% showed improvements in the Brainstem, Cerebral, Visual, and Bowel/Bladder FS. These findings indicate a broad treatment effect of alemtuzumab on multiple aspects of disability improvements. STUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.

Published
2018

42. Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332)

Author

Boyko, Alexey N, primary, Barnett, Michael, additional, Brassat, David, additional, Dive, Dominique, additional, Hupperts, Raymond MM, additional, Lycke, Jan, additional, Montalban, Xavier, additional, Sharrack, Basil, additional, Wray, Sibyl, additional, Margolin, David H, additional, Thangavelu, Karthinathan, additional, Chirieac, Madalina, additional, and Wiendl, Heinz, additional

Published
2017
Full Text
View/download PDF

43. Indications de l’autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques

Author

Zephir, Helène, Puyade, Mathieu, Gueguen, Antoine, Michel, Laure, Terriou, Louis, Dive, Dominique, Laureys, Guy, Mathey, Guillaume, Labauge, Pierre, Marjanovic, Zora, Pugnet, Grégory, Badoglio, Manuela, Lansiaux, Pauline, Yakoub-Agha, Ibrahim, Béguin, Yves, and Farge, Dominique

Abstract

Dans une démarche qui vise à uniformiser les procédures d’allogreffe et d’autogreffe de cellules souches hématopoïétiques, la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC) a organisé les huitièmes ateliers d’harmonisation des pratiques en allogreffe de cellules souches hématopoïétiques en septembre 2017 à Lille. Dans le contexte de cet atelier, il a été développé et mis à jour les indications et le suivi des autogreffes de cellules souches hématopoïétiques dans la sclérose en plaques sous l’égide de la SFGM-TC et de la Société francophone de la sclérose en plaques.

Published
2024
Full Text
View/download PDF

47. ENIGM: A French Observational Study about Switching from Natalizumab to Fingolimod in Multiple Sclerosis (S41.002)

Author

Cohen, Mikael, primary, Maillart, Elisabeth, additional, Papeix, Caroline, additional, Vukusic, Sandra, additional, Brassat, David, additional, De Seze, Jerome, additional, Tourbah, Ayman, additional, Wiertlewski, Sandrine, additional, Laplaud, David, additional, Courtois, Sylvie, additional, Derouiche, Faycal, additional, Chambaud, Loic, additional, Boulay, Clotilde, additional, Brochet, Bruno, additional, Debouverie, Marc, additional, Casez, Olivier, additional, Heinzlef, Olivier, additional, Ouallet, Jean, additional, Stankoff, Bruno, additional, Castelnovo, Giovanni, additional, Le Page, Emmanuelle, additional, Defer, Gilles, additional, Derache, Nathalie, additional, Anne, Olivier, additional, Berger, Eric, additional, Rumbach, Lucien, additional, Camdessanche, Jean-Phillippe, additional, Kopf, Audrey, additional, Fleury, Marie, additional, Malikova, Irina, additional, Pelletier, Jean, additional, Al Khedr, Abdullatif, additional, Zaenker, Christian, additional, Edan, Gilles, additional, Moreau, Thibault, additional, Fromont, Agnes, additional, Rico, Audrey, additional, Blanc, Frederic, additional, Collongues, Nicolas, additional, Barth, Pascal, additional, Louiset, Pierre, additional, Pittion, Sophie, additional, Clavelou, Pierre, additional, Taithe, Frederic, additional, Vermersch, Patrick, additional, Zephir, Helene, additional, Creange, Alain, additional, Gout, Olivier, additional, Guennoc, Anne Marie, additional, Coustans, Marc, additional, Taurin, Gregory, additional, Lallement, Francois, additional, Rouhart, Francois, additional, Camu, William, additional, Thouvenot, Eric, additional, Labauge, Pierre, additional, Dive, Dominique, additional, Seeldrayers, Pierrette, additional, and Lebrun Frenay, Christine, additional

Published
2013
Full Text
View/download PDF

50. (DXT65) Longitudinal Disability Follow-up in Patients with 6-Month Confirmed Disability Improvement or Worsening in the CARE-MS and Extension Studies.

Author

Hunter, Samuel F., Baker, Darren P., Ozog, Mark, Poole, Elizabeth M., Chung, Luke, Vermersch, Patrick, Aburashed, Rany A., Alroughani, Raed, Dive, Dominique, Ho Jin Kim, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, and Wiendl, Heinz

Subjects
CONFERENCES & conventions, PATIENT aftercare, MULTIPLE sclerosis, PEOPLE with disabilities, TIME
Abstract

Background: In the 2-year CARE-MS trials (trial registration: NCT00530348; NCT00548405), alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved clinical/magnetic resonance imaging outcomes vs subcutaneous interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS). Efficacy in alemtuzumab-treated patients was maintained through year 9 in 2 consecutive extension studies (NCT00930553; NCT02255656 [TOPAZ]). Objectives: To evaluate the status of disability over 9 years in pooled CARE-MS patients who had either 6-month confirmed disability improvement (CDI) or 6-month confirmed disability worsening (CDW) by years 2 or 9. Methods: Alemtuzumab-treated CARE-MS patients with baseline Expanded Disability Status Scale (EDSS) score ≥2 were stratified into 3 subgroups: with CDI, with CDW, or with stable disability. CDI and CDW were defined as ≥1-point decrease and increase, respectively, in EDSS score from core study baseline confirmed over 6 months. Improved and stable EDSS scores each year were defined as ≥1-point decrease and ≤0.5-point change in either direction, respectively, from core study baseline in available patients. Results: 511/811 (63%) alemtuzumab-treated patients had baseline EDSS score ≥2. Of these, 222 (43%) patients had 365 unique CDI events and 172 (34%) patients had 217 CDW events at any time during the 9-year study; 31 (6%) had both CDI and CDW. Few patients (n = 12) had a CDW event after CDI. Of patients with CDI at any time over 9 years, mean EDSS score change was --0.58 at year 9 vs core study baseline, and 51% had lower EDSS scores at year 9. Similar EDSS outcomes were observed at year 9 in the subset of patients who achieved CDI within the first 2 years of the study. However, patients with CDW any time over 9 years had worsened disability at year 9, with a +1.71 mean change in EDSS score from core study baseline; patients with CDW in the first 2 years of the study had a +2.27 EDSS score change by year 9. EDSS scores remained stable at 9 years (mean change, --0.10) in the 148 (29%) patients who had neither CDI nor CDW. Compared with previous years, no new safety signals were identified in year 9 in CARE-MS extension study patients. Conclusions: Achievement of CDI at any point in the CARE-MS studies was associated with improved disability at year 9 vs baseline. However, those with CDW had increased disability over 9 years regardless of when worsening occurred. These findings suggest that both CDI and CDW are meaningful end points for predicting long-term disability outcomes in patients with RRMS. [ABSTRACT FROM AUTHOR]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results